Table 3.
Comparison of All‐Cause Mortality During Follow‐Up, According to GDMT at Discharge
| Variable | Cumulative Incidence, No. %a | Univariate Analysis | IPW Adjusted Analysis | PS‐Matched Analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P Value | HR | 95% CI | P Value | HR | 95% CI | P Value | ||
| β‐Blocker at discharge | (375 pairs) | |||||||||
| No (n=524) | 183 (38.2) | 1.000 | Reference | NA | 1.000 | Reference | NA | 1.000 | Reference | NA |
| Yes (n=620) | 171 (30.7) | 0.758 | 0.615–0.934 | 0.009 | 0.827 | 0.708–0.967 | 0.017 | 0.734 | 0.565–0.954 | 0.021 |
| Renin‐angiotensin system blocker at discharge | (302 pairs) | |||||||||
| No (n=407) | 143 (38.1) | 1.000 | Reference | NA | 1.000 | Reference | NA | 1.000 | Reference | NA |
| Yes (n=737) | 211 (31.9) | 0.765 | 0.618–0.946 | 0.013 | 0.814 | 0.698–0.950 | 0.009 | 0.755 | 0.570–0.999 | 0.048 |
| Aldosterone antagonist at discharge | (362 pairs) | |||||||||
| No (n=711) | 218 (34.0) | 1.000 | Reference | NA | 1.000 | Reference | NA | 1.000 | Reference | NA |
| Yes (n=433) | 136 (34.2) | 1.063 | 0.858–1.317 | 0.578 | 1.138 | 0.974–1.330 | 0.103 | 1.176 | 0.904–1.526 | 0.229 |
CI indicates confidence interval; GDMT, guideline‐directed medical therapy; HR, hazard ratio; IPW, inverse probability weighted; NA, not applicable; PS, propensity score.
a
Cumulative incidences of all‐cause mortality are presented as Kaplan‐Meier estimates.